Cesca Therapeutics (NASDAQ:KOOL) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Cesca Therapeutics (NASDAQ:KOOL) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, Zacks.com reports. The firm currently has $3.25 price objective on the biotechnology company’s stock.

According to Zacks, “Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California. “

A number of other equities research analysts also recently weighed in on the stock. ValuEngine raised shares of Cesca Therapeutics from a hold rating to a buy rating in a research report on Tuesday, July 2nd. HC Wainwright reaffirmed a buy rating and set a $6.50 price objective (up previously from $1.00) on shares of Cesca Therapeutics in a research report on Wednesday, August 14th.

Shares of Cesca Therapeutics stock opened at $3.09 on Tuesday. The firm’s 50-day simple moving average is $3.11 and its 200-day simple moving average is $1.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.91 and a current ratio of 1.52. Cesca Therapeutics has a 1 year low of $2.10 and a 1 year high of $5.25.

Cesca Therapeutics (NASDAQ:KOOL) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.13. The business had revenue of $4.31 million for the quarter, compared to analyst estimates of $3.40 million. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. As a group, equities research analysts expect that Cesca Therapeutics will post -0.45 earnings per share for the current year.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Featured Story: Buy-Side Analysts

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.